ES2655026T3 - Compuestos farmacológicamente activos - Google Patents

Compuestos farmacológicamente activos Download PDF

Info

Publication number
ES2655026T3
ES2655026T3 ES13760107T ES13760107T ES2655026T3 ES 2655026 T3 ES2655026 T3 ES 2655026T3 ES 13760107 T ES13760107 T ES 13760107T ES 13760107 T ES13760107 T ES 13760107T ES 2655026 T3 ES2655026 T3 ES 2655026T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
heteroaryl
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13760107T
Other languages
English (en)
Spanish (es)
Inventor
Swen Hoelder
Julian Blagg
Kwai-Ming J. Cheung
Butrus Atrash
Peter SHELDRAKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2655026T3 publication Critical patent/ES2655026T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13760107T 2012-09-07 2013-09-09 Compuestos farmacológicamente activos Active ES2655026T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1216018.0A GB201216018D0 (en) 2012-09-07 2012-09-07 Pharmacologically active compounds
PCT/GB2013/052361 WO2014037751A1 (en) 2012-09-07 2013-09-09 Pharmacologically active compounds

Publications (1)

Publication Number Publication Date
ES2655026T3 true ES2655026T3 (es) 2018-02-16

Family

ID=47137118

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13760107T Active ES2655026T3 (es) 2012-09-07 2013-09-09 Compuestos farmacológicamente activos

Country Status (6)

Country Link
US (3) US9334286B2 (enExample)
EP (1) EP2892890B1 (enExample)
JP (1) JP6297570B2 (enExample)
ES (1) ES2655026T3 (enExample)
GB (1) GB201216018D0 (enExample)
WO (1) WO2014037751A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216018D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
WO2018234778A1 (en) * 2017-06-20 2018-12-27 The Institute Of Cancer Research: Royal Cancer Hospital METHODS AND MEDICAL USES
KR102777989B1 (ko) * 2017-11-30 2025-03-12 한미약품 주식회사 4-아미노-N-(1-((3-클로로-2-플루오로페닐)아미노)-6-메틸이소퀴놀린-5-일)티에노[3,2-d]피리미딘-7-카르복사미드의 염, 및 그의 결정질 형태
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN112174903B (zh) * 2019-07-01 2022-07-12 清华大学 Tlr8的小分子调节剂
CA3156268A1 (en) * 2019-10-01 2021-04-08 Goldfinch Bio, Inc. CDK5 SUBSTITUTE 1,6-NAPHTYRIDINE INHIBITORS
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
CA3240400A1 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
CN116410189B (zh) * 2021-12-30 2024-08-06 中国科学院上海药物研究所 一种嘧啶并吡啶类化合物及其药用组合物和应用
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
WO2001055147A1 (en) 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002009036A2 (en) 2000-07-21 2002-01-31 The Trustees Of Columbia University In The City Of New York Method and apparatus for reducing distortion in images
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002324450A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
RU2301233C2 (ru) 2002-03-07 2007-06-20 Ф.Хоффманн-Ля Рош Аг Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
PL376751A1 (pl) 2002-11-12 2006-01-09 Abbott Laboratories Bicykliczne podstawione aminy jako ligandy receptora histaminowego-3
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
WO2008079988A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
EP2183254B1 (en) 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
CN102596946B (zh) 2009-08-05 2015-06-17 港大科桥有限公司 抗病毒化合物及其制备和使用方法
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
ES2539972T3 (es) 2010-07-30 2015-07-07 Nerviano Medical Sciences S.R.L. Isoxazolo-quinazolinas como moduladores de la actividad de proteina cinasa
ES2377610B1 (es) * 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
RU2591191C2 (ru) 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
US10188642B2 (en) 2019-01-29
US9895364B2 (en) 2018-02-20
US20160296514A1 (en) 2016-10-13
EP2892890B1 (en) 2017-11-22
EP2892890A1 (en) 2015-07-15
US9334286B2 (en) 2016-05-10
JP2015529217A (ja) 2015-10-05
US20150218181A1 (en) 2015-08-06
US20180117032A1 (en) 2018-05-03
WO2014037751A1 (en) 2014-03-13
JP6297570B2 (ja) 2018-03-20
GB201216018D0 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
CO5320600A1 (es) Agentes antibacterianos de 3-aminoquinazolin-2,4-dionas
AR060525A1 (es) Piridin [3,4-b] pirazinonas. composiciones farmaceuticas
AR036779A1 (es) 7-aza[2.2.1]bicicloheptanos sustituidos, su uso para el tratamiento de enfermedades donde un mamifero recibe alivio sintomatico de un agonista de acetilcolina a7 nicotinico y composiciones farmaceuticas que lo contienen
AR047678A1 (es) Derivados de benzamidas y su uso como activadores de glucoquinasa
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
AR048523A1 (es) Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
AR065280A1 (es) Agentes antiparasitarios
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR040048A1 (es) Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6
JP2015529217A5 (enExample)
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
ECSP10010414A (es) Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos
RU2010102229A (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR080467A1 (es) Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades
AR064182A1 (es) Inhibidores macrociclicos de serina proteasa de hepatitis c y sus usos
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR064521A1 (es) Activador de glucoquinasa